Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Industry Attractiveness - Porter Five Forces
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry


5 Market Segmentation
5.1 By Component
5.1.1 Sensors
5.1.2 Durables (Receivers and Transmitters)
5.2 CGM Device Users
5.2.1 New South Wales
5.2.2 Victoria
5.2.3 Queensland
5.2.4 South Australia
5.2.5 Western Australia
5.2.6 Tasmania
5.2.7 Northern Territory
5.2.8 Australian Capital Territory
5.3 By Provinces
5.3.1 New South Wales
5.3.2 Victoria
5.3.3 Queensland
5.3.4 South Australia
5.3.5 Western Australia
5.3.6 Tasmania
5.3.7 Northern Territory
5.3.8 Australian Capital Territory
5.4 Market Share by Public and Private
5.5 Analysis of CGM Devices Distribution Channels (Includes percentage share of Hospitals, clinics, Pharmacies, and other modes)
5.6 Analysis of CGM devices prescribers (includes percentage share of Endocrinologists, Diabetologist, and other HCP specialties, and Prescribers knowledge of CGM devices)


6 Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population


7 Analyst Perspective - The Impact of COVID-19 Impact on the Market


8 COMPETITIVE LANDSCAPE
8.1 Company Profiles
8.1.1 Abbott Diabetes Care Inc.
8.1.2 Dexcom Inc.
8.1.3 Medtronic PLC
8.1.4 Eversense
8.1.5 Ascensia
8.2 Company Share Analysis
8.2.1 Abbott Diabetes Care Inc.
8.2.2 Dexcom Inc.
8.2.3 Medtronic PLC
8.2.4 Other Companies


9 MARKET OPPORTUNITIES AND FUTURE TRENDS